Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial Active — Not Recruiting Non-phase study NCT05412940

Accelerometry and Rehabilitation After Knee Replacement Study (ARK)

Accelerometry and Rehabilitation After Knee Replacement Study (ARK) — Active Not Recruiting • Non-phase study • Infectious Disease • NCT05412940.

📅 10 Sep 2026 ⏱ 2 min read
Active — Not Recruiting
Check the registry for current status and eligibility criteria.
Status
Active — Not Recruiting
Phase
Non-phase study
NCT ID
NCT05412940
Start
2022-05-20
Completion
2026-09-01
ClinicaliQ Trial Snapshot
  • Accelerometry and Rehabilitation After Knee Replacement Study (ARK) — Active Not Recruiting • Non-phase study • Infectious Disease • NCT05412940.
  • Wearable sensors with remote monitoring may improve exercise compliance and outcomes after knee replacement compared to standard physiotherapy.

Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

Total knee replacement (TKR) is a successful and cost-effective treatment for end-stage arthritis. Its usage is increasing due to changing population demographics and quality of life (QoL) expectations. There were almost 100,000 total knee replacements (TKR) performed in England between 2018/19. After TKR, patient engagement in their rehabilitation exercises is very important but physiotherapy services are very stretched at present especially in the covid-19 era. Patient compliance with their exercises is poor at about 25%. The use of wearable sensors (WS) following TKR is gaining lots of interest especially in…

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Clinical Brief
Same-day test ‘saved her life’
Infectious Disease · BBC Health · 16 Oct 2026
Same-day infection detection test shows promise for ICU patients, potentially enabling faster diagnosis and earlier treatment initiation compared to conventional culture methods…
View brief →
Clinical Brief
IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review
Infectious Disease · MHRA · 20 Oct 2026
IXCHIQ chikungunya vaccine marketing authorisation withdrawn in UK following CHM safety review, indicating benefit-risk profile no longer favourable Clinicians should cease prescribing…
View brief →
Clinical Brief
Genital herpes rising in England
Infectious Disease · BBC Health · 03 Jun 2026
Genital herpes cases are rising in England, contrasting with declining trends in other STIs, suggesting targeted prevention and screening strategies may be…
View brief →
Clinical Brief
‘My eyelids became infected – I was scared to sleep’
Infectious Disease · BBC Health · 23 Sep 2026
Key Takeaways for Clinical Practice Unregulated cosmetic tourism carries significant infection risks – patients undergoing blepharoplasty abroad face complications including serious eyelid…
View brief →
Clinical Brief
Heavy periods study to create world’s largest biobank
Infectious Disease · BBC Health · 26 Aug 2026
A new biobank of menstrual fluid samples is being established to identify biomarkers and improve understanding of heavy menstrual bleeding pathophysiology, potentially…
View brief →
Clinical Brief
£33.2m to protect public from future epidemics and pandemics
Infectious Disease · UKHSA · 08 Oct 2026
Eight new vaccine projects will receive £33.2m funding to develop treatments against high-threat pathogens, enhancing the UK's pandemic preparedness capabilities Funding focuses…
View brief →